LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- The “Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2029” report offered by GlobalData provides an overview of AML including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Additionally, the report analyses topline AML market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
The sales of AML therapeutics totaled $1.4 billion in 2019. The AML market is anticipated to experience growth at a CAGR of more than 13% by 2029. The global market growth is driven by the launch of 16 new pipeline agents in the 7MM and 12 in China, by the introduction of currently US-exclusive agents in the 5EU and Asia, and by label expansions in the US.
For more comprehensive statistics on AML market sizing and forecast, download a sample report
Acute Myeloid Leukemia Market Drivers
- The introduction of 16 new branded agents in the 7MM and 12 in China during the forecast period will greatly expand the size of the global market.
- The exceptional commercial success of Venclexta with further label expansion in all countries, making it the global standard of care (SOC) for elderly patients without IDH1/2 mutations receiving firstline therapy.
- The recent rise in biomarker testing in Japan and China will allow the gradual adoption of premium-priced FLT3 inhibitors and IDH1/2 inhibitors, resulting in more personalized AML care globally.
For more insights on AML market drivers and challenges, download a sample report
Acute Myeloid Leukemia Market - Unmet Needs and Opportunities Assessment
In the AML market, the level of unmet need is high, with key opinion leaders (KOLs) pointing out that a high level of unmet need is present across the entire field. The existing drugs can readily offer complete remissions in young patients, which however do not always translate to long-term survival, due to the poor prognosis of the high-risk cytogenetics group and due to graft-versus-host disease (GVHD) or other transplant-related complications. The vast majority of patients, particularly elderly patients or patients with secondary AML, ultimately relapse after therapy, even after allogeneic transplant, and are the two patient populations in dire need of better outcomes. Furthermore, the elderly population needs safer compounds that are more conveniently administered, consequently reducing hospital visits. Thus, overall in this market, there is certainly room for new entrants provided that they can demonstrate effective long-term disease control.
For more insights on unmet needs and opportunities in the AML market, download a sample report
Acute Myeloid Leukemia Market - Pipeline Assessment
Given the high level of unmet need, a new agent that is effective in AML could easily demand premium pricing. GlobalData views the pipeline as strong, with 16 promising candidates in late-stage development. Regulatory approval of new agents, as well as label expansion of previously approved ones, is expected to significantly erode market share from generic chemotherapy over the forecast period. Many late-stage pipeline drugs are also in early-stage development for additional AML patient segments, in order to maximize their revenue. As a result, global AML sales are projected to grow sharply across the forecast period to 2029.
For more insights on the AML drugs pipeline and forecast, download a sample report
Acute Myeloid Leukemia Market - Competitive Landscape
In the low-intensity first-line space, Venclexta is set to remain the market leader, followed closely by the launch of cusatuzumab, which is of high expected clinical and commercial potential. The intensive induction space will see significant adoption of FLT3 inhibitors, with Xospata having both a clinical and commercial advantage over Vanflyta and crenolanib.
Leading Companies in the Acute Myeloid Leukemia Market
- Rafael Pharmaceuticals Inc
- Arog Pharmaceuticals Inc
- Delta-Fly Pharma Inc
- SELLAS Life Sciences Group Inc
- Astex Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- Actinium Pharmaceuticals Inc
- Gamida Cell Ltd
- Millennium Pharmaceuticals Inc
- Helsinn Healthcare
To know more about leading companies in the AML market, download a sample report
Acute Myeloid Leukemia Market Report Scope
- Overview of acute myeloid leukemia including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline acute myeloid leukemia market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting acute myeloid leukemia therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
- Analysis of the current and future market competition in the global acute myeloid leukemia therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global acute myeloid leukemia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global acute myeloid leukemia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global acute myeloid leukemia therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Related Reports
- Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
- Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here
- Metastatic Melanoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update – Click here
- Electronic Health Records (EHRs) – Analyzing Trends, Technologies, Physicians’ Adoption and Perceptions, Use Barriers and Opportunities, and Future Prospects – Click here
- Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
Acute Myeloid Leukemia Market Overview
| Market Size 2019 | $1.4 billion |
| CAGR (2019-2029) | >13% |
| Leading Companies | Rafael Pharmaceuticals Inc, Arog Pharmaceuticals Inc, Delta-Fly Pharma Inc, SELLAS Life Sciences Group Inc, Astex Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Actinium Pharmaceuticals Inc, Gamida Cell Ltd, Millennium Pharmaceuticals Inc, Helsinn Healthcare, and Others |
FAQs
What was the acute myeloid leukemia market size in 2019?
The AML market size was valued at $1.4 billion in 2019.
What is the acute myeloid leukemia market growth rate?
The AML market is expected to grow at a CAGR of more than 13% during the forecast period.
Which are the leading companies in the acute myeloid leukemia market?
The leading companies in the AML market are Rafael Pharmaceuticals Inc, Arog Pharmaceuticals Inc, Delta-Fly Pharma Inc, SELLAS Life Sciences Group Inc, Astex Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Actinium Pharmaceuticals Inc, Gamida Cell Ltd, Millennium Pharmaceuticals Inc, Helsinn Healthcare, and others.
Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Acute Myeloid Leukemia: Executive Summary
2.1 The Acute Myeloid Leukemia Market Size Will Grow at a
13.6% Rate During 2019–2029
2.2 Recent Approvals and Novel Agents Drive Competition in the First-Line Induction Setting but the Relapsed/Refractory Market Remains Underserved
2.2.1 Key Drug Developers in Acute Myeloid Leukemia
2.3 Poor Long-Term Survival Remains an Unmet Need and Provides Opportunity for New Market Entrants
2.4 Increased Adoption of Targeted Therapies and Introduction of Immunotherapies Poised to Change the Treatment Paradigm
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used and Not Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for AML (2019–2029)
5.5.1 Diagnosed Incident Cases of AML
5.5.2 Age-Specific Diagnosed Incident Cases of AML
5.5.3 Sex-Specific Diagnosed Incident Cases of AML
5.5.4 Diagnosed Incident Cases of AML by Risk Group
5.5.5 Diagnosed Incident Cases of Secondary AML
5.5.6 Diagnosed Incident Cases of APL
5.5.7 Five-Year Diagnosed Prevalent Cases of AML
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Coronavirus Disease 2019 (COVID-19) Impact
5.6.3 Limitations of Analysis
5.6.4 Strengths of Analysis
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Outcomes in Secondary AML
7.3 Translating Complete Response to Durable, Five-Year Survival
7.4 Treatments in the Second Line and Beyond
7.5 Improved Options for Older Patients
7.6 Improved Outcomes after Transplant
8 R&D Strategies
8.1 Overview
8.1.1 Improved Cytotoxic Agents
8.1.2 Exploiting AML Vulnerabilities
8.1.3 Next-Generation Targeted Therapies
8.1.4 Revisiting Immunotherapies
8.2 Clinical Trials Design
8.2.1 Important Trials
8.2.2 Primary and Secondary Endpoints
8.2.3 Comparison Arm
8.2.4 Choice of Patients
8.2.5 Future Trends
9 Pipeline Assessment
9.1 Overview
9.2 Innovative Early-Stage Approaches
9.3 Other Drugs in Development
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
10.4.4 China
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Generic Erosion
11.3.9 Pricing of Pipeline Agents
11.4 Primary Research – KOLs Interviewed for This Report
11.4.1 KOLs
11.5 Primary Research – Prescriber Survey
11.6 About the Authors
11.6.1 Analysts
11.6.2 Therapy Area Director
11.6.3 Epidemiologist
11.6.4 Managing Epidemiologist
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About GlobalData
11.8 Contact Us
11.9 Disclaimer
About us
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com
+44 (0)207 936 6400
